PMID- 23807519
OWN - NLM
STAT- MEDLINE
DCOM- 20140721
LR  - 20221207
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 19
IP  - 6
DP  - 2013 Nov-Dec
TI  - Glycemic control and diabetic dyslipidemia in adolescents with type 2 diabetes.
PG  - 972-9
LID - 10.4158/EP13016.OR [doi]
AB  - OBJECTIVE: The incidence of type 2 diabetes mellitus (T2DM) is increasing at an 
      alarming rate, especially in ethnic minorities, and T2DM is associated with 
      significant comorbidities. The primary objective of this study was to assess 
      glycemic control and cardiovascular risk outcomes in children with T2DM at 1 year 
      after diagnosis. We also assessed whether insulin treatment at onset of diabetes 
      is beneficial for overall outcome in those with elevated glycated hemoglobin 
      (HbA1C). METHODS: A retrospective electronic chart review of non-Hispanic white 
      (NHW) and African American (AA) children with T2DM. RESULTS: A total of 86 
      patients (66.3% females, 79.1% AA, mean age, 13.8 +/- 2.4 years) with T2DM were 
      included. Analyses of therapeutic outcome measures at the 1-year follow-up showed 
      HbA1C >8% in 27.7% of patients, low-density-lipoprotein cholesterol (LDL-C) >130 
      mg/dL in 12.5%, non-high-density-lipoprotein cholesterol (non-HDL-C) >160 mg/dL 
      in 15.6%, HDL-C <35 mg/dL in 25%, systolic hypertension (HTN) in 35.6%, and 
      diastolic HTN in 6.8% of subjects. Among those started on insulin at initial 
      diagnosis, there was significant improvement in glycemic outcomes (P<.0001 on 
      insulin vs. P = .02 not on insulin) and dyslipidemia (total cholesterol [TC] [P = 
      .001], LDL-C [P = .02], HDL-C [P = .01], non-HDL-C [P = .0002], and TC/HDL-C [P = 
      .005]) compared with no significant change among those who did not receive 
      insulin at diagnosis. CONCLUSION: Substantial numbers of children with T2DM do 
      not achieve glycemic and cardiovascular therapeutic goals 1 year after diagnosis. 
      Insulin therapy at diagnosis has significant beneficial effects on diabetic 
      dyslipidemia in those with higher HbA1C.
FAU - Le, Phuong Thanh
AU  - Le PT
AD  - UAB School of Medicine, University of Alabama at Birmingham.
FAU - Huisingh, Carrie Ellen
AU  - Huisingh CE
FAU - Ashraf, Ambika P
AU  - Ashraf AP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adolescent
MH  - Black or African American
MH  - Blood Glucose/*metabolism
MH  - Cardiovascular Diseases/epidemiology
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Cohort Studies
MH  - Diabetes Complications/epidemiology
MH  - Diabetes Mellitus, Type 2/drug therapy/*metabolism
MH  - Dyslipidemias/drug therapy/*metabolism
MH  - Electronic Health Records
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypertension/complications
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Factors
MH  - White People
EDAT- 2013/06/29 06:00
MHDA- 2014/07/22 06:00
CRDT- 2013/06/29 06:00
PHST- 2013/06/29 06:00 [entrez]
PHST- 2013/06/29 06:00 [pubmed]
PHST- 2014/07/22 06:00 [medline]
AID - S1530-891X(20)43117-9 [pii]
AID - 10.4158/EP13016.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2013 Nov-Dec;19(6):972-9. doi: 10.4158/EP13016.OR.